Cargando…
MGMT Promoter Methylation: Prognostication beyond Treatment Response
MGMT promoter methylation is related to the increased sensitivity of tumour tissue to chemotherapy with temozolomide (TMZ) and thus to improved patient survival. However, it is unclear how the extent of MGMT promoter methylation affects outcomes. In our study, a single-centre retrospective study, we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302387/ https://www.ncbi.nlm.nih.gov/pubmed/37373988 http://dx.doi.org/10.3390/jpm13060999 |
_version_ | 1785065034301308928 |
---|---|
author | Ashkan, Keyoumars Baig Mirza, Asfand Soumpasis, Christos Syrris, Christoforos Kalaitzoglou, Dimitrios Sharma, Chaitanya James, Zachariah Joseph Khoja, Abbas Khizar Ahmed, Razna Vastani, Amisha Bartram, James Chia, Kazumi Al-Salihi, Omar Swampilai, Angela Brazil, Lucy Laxton, Ross Reisz, Zita Bodi, Istvan King, Andrew Gullan, Richard Vergani, Francesco Bhangoo, Ranjeev Al-Sarraj, Safa Lavrador, Jose Pedro |
author_facet | Ashkan, Keyoumars Baig Mirza, Asfand Soumpasis, Christos Syrris, Christoforos Kalaitzoglou, Dimitrios Sharma, Chaitanya James, Zachariah Joseph Khoja, Abbas Khizar Ahmed, Razna Vastani, Amisha Bartram, James Chia, Kazumi Al-Salihi, Omar Swampilai, Angela Brazil, Lucy Laxton, Ross Reisz, Zita Bodi, Istvan King, Andrew Gullan, Richard Vergani, Francesco Bhangoo, Ranjeev Al-Sarraj, Safa Lavrador, Jose Pedro |
author_sort | Ashkan, Keyoumars |
collection | PubMed |
description | MGMT promoter methylation is related to the increased sensitivity of tumour tissue to chemotherapy with temozolomide (TMZ) and thus to improved patient survival. However, it is unclear how the extent of MGMT promoter methylation affects outcomes. In our study, a single-centre retrospective study, we explore the impact of MGMT promoter methylation in patients with glioblastoma who were operated upon with 5-ALA. Demographic, clinical and histology data, and survival rates were assessed. A total of 69 patients formed the study group (mean age 53.75 ± 15.51 years old). Positive 5-ALA fluorescence was noted in 79.41%. A higher percentage of MGMT promoter methylation was related to lower preoperative tumour volume (p = 0.003), a lower likelihood of 5-ALA positive fluorescence (p = 0.041) and a larger extent of resection EoR (p = 0.041). A higher MGMT promoter methylation rate was also related to improved progression-free survival (PFS) and overall survival (OS) (p = 0.008 and p = 0.006, respectively), even when adjusted for the extent of resection (p = 0.034 and p = 0.042, respectively). A higher number of adjuvant chemotherapy cycles was also related to longer PFS and OS (p = 0.049 and p = 0.030, respectively). Therefore, this study suggests MGMT promoter methylation should be considered as a continuous variable. It is a prognostic factor that goes beyond sensitivity to chemotherapy treatment, as a higher percentage of methylation is related not only to increased EoR and increased PFS and OS, but also to lower tumour volume at presentation and a lower likelihood of 5-ALA fluorescence intraoperatively. |
format | Online Article Text |
id | pubmed-10302387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103023872023-06-29 MGMT Promoter Methylation: Prognostication beyond Treatment Response Ashkan, Keyoumars Baig Mirza, Asfand Soumpasis, Christos Syrris, Christoforos Kalaitzoglou, Dimitrios Sharma, Chaitanya James, Zachariah Joseph Khoja, Abbas Khizar Ahmed, Razna Vastani, Amisha Bartram, James Chia, Kazumi Al-Salihi, Omar Swampilai, Angela Brazil, Lucy Laxton, Ross Reisz, Zita Bodi, Istvan King, Andrew Gullan, Richard Vergani, Francesco Bhangoo, Ranjeev Al-Sarraj, Safa Lavrador, Jose Pedro J Pers Med Article MGMT promoter methylation is related to the increased sensitivity of tumour tissue to chemotherapy with temozolomide (TMZ) and thus to improved patient survival. However, it is unclear how the extent of MGMT promoter methylation affects outcomes. In our study, a single-centre retrospective study, we explore the impact of MGMT promoter methylation in patients with glioblastoma who were operated upon with 5-ALA. Demographic, clinical and histology data, and survival rates were assessed. A total of 69 patients formed the study group (mean age 53.75 ± 15.51 years old). Positive 5-ALA fluorescence was noted in 79.41%. A higher percentage of MGMT promoter methylation was related to lower preoperative tumour volume (p = 0.003), a lower likelihood of 5-ALA positive fluorescence (p = 0.041) and a larger extent of resection EoR (p = 0.041). A higher MGMT promoter methylation rate was also related to improved progression-free survival (PFS) and overall survival (OS) (p = 0.008 and p = 0.006, respectively), even when adjusted for the extent of resection (p = 0.034 and p = 0.042, respectively). A higher number of adjuvant chemotherapy cycles was also related to longer PFS and OS (p = 0.049 and p = 0.030, respectively). Therefore, this study suggests MGMT promoter methylation should be considered as a continuous variable. It is a prognostic factor that goes beyond sensitivity to chemotherapy treatment, as a higher percentage of methylation is related not only to increased EoR and increased PFS and OS, but also to lower tumour volume at presentation and a lower likelihood of 5-ALA fluorescence intraoperatively. MDPI 2023-06-14 /pmc/articles/PMC10302387/ /pubmed/37373988 http://dx.doi.org/10.3390/jpm13060999 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ashkan, Keyoumars Baig Mirza, Asfand Soumpasis, Christos Syrris, Christoforos Kalaitzoglou, Dimitrios Sharma, Chaitanya James, Zachariah Joseph Khoja, Abbas Khizar Ahmed, Razna Vastani, Amisha Bartram, James Chia, Kazumi Al-Salihi, Omar Swampilai, Angela Brazil, Lucy Laxton, Ross Reisz, Zita Bodi, Istvan King, Andrew Gullan, Richard Vergani, Francesco Bhangoo, Ranjeev Al-Sarraj, Safa Lavrador, Jose Pedro MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title | MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title_full | MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title_fullStr | MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title_full_unstemmed | MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title_short | MGMT Promoter Methylation: Prognostication beyond Treatment Response |
title_sort | mgmt promoter methylation: prognostication beyond treatment response |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302387/ https://www.ncbi.nlm.nih.gov/pubmed/37373988 http://dx.doi.org/10.3390/jpm13060999 |
work_keys_str_mv | AT ashkankeyoumars mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT baigmirzaasfand mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT soumpasischristos mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT syrrischristoforos mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT kalaitzogloudimitrios mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT sharmachaitanya mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT jameszachariahjoseph mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT khojaabbaskhizar mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT ahmedrazna mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT vastaniamisha mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT bartramjames mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT chiakazumi mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT alsalihiomar mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT swampilaiangela mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT brazillucy mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT laxtonross mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT reiszzita mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT bodiistvan mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT kingandrew mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT gullanrichard mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT verganifrancesco mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT bhangooranjeev mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT alsarrajsafa mgmtpromotermethylationprognosticationbeyondtreatmentresponse AT lavradorjosepedro mgmtpromotermethylationprognosticationbeyondtreatmentresponse |